Teladoc Health (NYSE:TDOC) Upgraded at Bank of America

Bank of America upgraded shares of Teladoc Health (NYSE:TDOC) from a neutral rating to a buy rating in a report issued on Thursday, MarketBeat reports. They currently have $7.00 price target on the health services provider’s stock.

Several other research analysts have also weighed in on the stock. Wells Fargo & Company lowered their target price on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday. Piper Sandler reaffirmed an “overweight” rating and issued a $9.00 price target (down from $12.00) on shares of Teladoc Health in a report on Thursday. Evercore cut their target price on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research report on Thursday, October 30th. Citigroup lowered their price objective on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Friday, January 9th. Finally, BMO Capital Markets assumed coverage on shares of Teladoc Health in a research report on Thursday, November 13th. They issued a “market perform” rating and a $8.00 price objective on the stock. Four analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Teladoc Health has an average rating of “Hold” and a consensus target price of $7.80.

Teladoc Health Trading Down 1.8%

Shares of NYSE:TDOC opened at $5.25 on Thursday. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $9.94. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. The business’s 50 day moving average price is $5.99 and its 200-day moving average price is $7.20. The firm has a market capitalization of $932.25 million, a price-to-earnings ratio of -4.61 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The business had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.09%. The company’s revenue for the quarter was up .3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. On average, equities research analysts forecast that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Insider Transactions at Teladoc Health

In related news, insider Carlos Nueno sold 3,897 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total value of $29,188.53. Following the transaction, the insider owned 27,175 shares in the company, valued at approximately $203,540.75. The trade was a 12.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Charles Divita III sold 17,138 shares of the stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the transaction, the chief executive officer owned 201,036 shares in the company, valued at $1,533,904.68. This trade represents a 7.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 33,288 shares of company stock valued at $251,684. 0.58% of the stock is currently owned by company insiders.

Institutional Trading of Teladoc Health

Several hedge funds have recently bought and sold shares of the company. Allianz Asset Management GmbH raised its stake in shares of Teladoc Health by 189.2% during the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock valued at $12,518,000 after purchasing an additional 1,059,458 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Teladoc Health during the 2nd quarter worth about $2,722,000. Jupiter Asset Management Ltd. purchased a new stake in shares of Teladoc Health in the third quarter valued at $7,576,000. Banco Bilbao Vizcaya Argentaria S.A. boosted its position in Teladoc Health by 23.1% during the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 212,933 shares of the health services provider’s stock worth $1,841,000 after acquiring an additional 39,956 shares during the period. Finally, Empowered Funds LLC acquired a new stake in Teladoc Health during the second quarter valued at $5,040,000. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and narrower loss — Teladoc posted Q4 revenue of $642.3M (above Street) and a GAAP loss of $0.14/sh that was better than expected; management highlighted international and Integrated Care strength that helped offset weakness at BetterHelp. Teladoc Tops Q4 Earnings
• Positive Sentiment: Medium‑term revenue guidance and strategic initiatives — Management projected 2026 revenue of $2.47B–$2.59B and emphasized AI, insurance partnerships and international expansion as growth levers. That gives investors a multi‑year growth narrative beyond the quarter. 2026 Revenue Projection
• Positive Sentiment: Some analyst support remains — Bank of America upgraded TDOC to Buy (PT $7) and a few firms (Canaccord, Piper Sandler) kept positive/overweight stances despite trimming targets, signaling conviction among some analysts that upside exists from current levels. Analyst Reviews
• Neutral Sentiment: Earnings call details and metrics — Management’s earnings call and transcript provide context on segment trends (Integrated Care up, BetterHelp down) and KPI performance; useful for assessing sustainability of the beat. Earnings Call Highlights
• Negative Sentiment: Near‑term guidance and outlook caution — Q1 revenue guide (~$609M) and FY EPS guidance were conservative and Q1 revenue guidance came in below some estimates, creating uncertainty over short‑term growth and profitability. Q4 & Guidance Release
• Negative Sentiment: Multiple price‑target cuts — Several firms trimmed targets (examples: BMO to $5.00, Leerink to $5.50, Cowen/Wells Fargo/Stifel to $6.00 ranges), and some moved to market‑perform/hold — this fresh downdraft from sell‑side revisions pressures sentiment despite the beat. Analyst Target Moves

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.